Smartlab Europe

Dr. Reddys Says Russia Sales Booming As Big Pharma Retreats

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

The Invisible Costs Undermining Pharma Profit Margins and the Digital Fixes Gaining Traction

Pharmaceutical companies spend extraordinary amounts optimising what they can...

SGD Pharma Advances Nasal Drug Delivery with Prince Deal

SGD Pharma has entered into a Franco-American OEM collaboration...

Structural Pricing Pressure is Reshaping Pharma in 2026

In 2026, global pricing pressure in the pharmaceutical sector has shifted from a temporary, cyclical issue to a structural constraint. Explore how U.S. reforms, European reference pricing, and biosimilar competition are forcing companies to embed pricing risk into core strategy.
- Advertisement -

While many western biopharma businesses have shied away from Russia since its invasion of Ukraine, some of those in India have stepped in to fill the hole by providing the Kremlin with medical supplies. Dr. Reddy’s Laboratories has been one of the Indian companies spearheading the move into Russia while simultaneously attempting to overcome logistical hurdles in delivering medications to Ukraine. Dr. Reddy’s announced plans to sell new medications in Russia during its quarterly profit release recently. The company, which ranks fourth among India’s drugmakers in terms of market capitalization, is doing exceptionally well in Russia. Its sales in Russia climbed by 70% year over year in the prior quarter. GV Prasad, Dr.  Reddy’s co-chairman and managing director, confirmed that their Russian operations will continue as usual. During the early stages of this ongoing crisis, their customers did some inventory stockpiling. They expect that to return to normal in the next quarter.

While several European and American pharmaceutical companies have increased humanitarian aid to Ukraine and shut down their activities in Russia, companies like Dr. Reddy’s have continued to supply the country with medications.

Several Indian companies have continued doing business as usual in Russia. India is in a precarious situation. To defend itself from China, the country has enlisted the help of both Russia and Europe.

The government has been silent on the Russian incursion and has refused to denounce it. Painkillers and other medications are sold in Russia by Dr. Reddy’s. They are also India’s principal supplier of Russia’s Sputnik COVID-19 vaccine. Sales to Russia amounted to more than 8% of the company’s revenue in the preceding fiscal year, which ended in March 2021, totaling $2.47 billion.

Despite delivery issues, Dr. Reddy’s said it is attempting to continue supplying pharmaceuticals to Ukraine. There has been no stoppage of funds from Russia, according to the company. Dr. Reddy’s CEO of branded markets, MV Ramana remarked that they have been in the country for three decades now and are continuing to operate as usual. Their employees’ safety has been prioritised.

Latest stories

Related stories

The Invisible Costs Undermining Pharma Profit Margins and the Digital Fixes Gaining Traction

Pharmaceutical companies spend extraordinary amounts optimising what they can...

SGD Pharma Advances Nasal Drug Delivery with Prince Deal

SGD Pharma has entered into a Franco-American OEM collaboration...

Structural Pricing Pressure is Reshaping Pharma in 2026

In 2026, global pricing pressure in the pharmaceutical sector has shifted from a temporary, cyclical issue to a structural constraint. Explore how U.S. reforms, European reference pricing, and biosimilar competition are forcing companies to embed pricing risk into core strategy.

Merck Targets $70B Revenue in 2026 with Cidara Deal

Merck’s roughly $9.2 billion acquisition of Cidara Therapeutics and its $70 billion revenue ambition mark a strategic pivot toward respiratory vaccines and antivirals. Explore how this deal reshapes Merck’s portfolio and signals a broader industry shift toward targeted M&A to offset patent cliffs.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »